Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13330959 | 1.00 | MEN1 (0.34) | MEN1MAPK1KMT2AHDAC4HDAC1 | |
| SCHEMBL8247730 | 0.87 | MEN1 (0.35) | MEN1MAPK1KMT2AHDAC4HDAC1 | |
| SCHEMBL13360949 | 0.81 | MEN1 (0.37) | MEN1MAPK1KMT2AHDAC4HDAC1 | |
| SCHEMBL13629869 | 0.79 | SMN1; SMN2 (0.34) | MEN1MAPK1KMT2AHDAC4HDAC1 | |
| SCHEMBL7917188 | 0.72 | MEN1 (0.36) | MEN1MAPK1KMT2AHDAC4HDAC1 | |
| SCHEMBL6886964 | 0.72 | MEN1 (0.36) | MEN1MAPK1KMT2AHDAC4HDAC1 | |
| SCHEMBL16062006 | 0.71 | MEN1 (0.38) | MEN1MAPK1KMT2ANFKB1NFKB2 | |
| SCHEMBL6884524 | 0.71 | MEN1 (0.35) | MEN1MAPK1KMT2AHDAC4HDAC1 | |
| SCHEMBL24981405 | 0.71 | MEN1 (0.39) | MEN1MAPK1KMT2AHDAC4HDAC1 | |
| SCHEMBL13924261 | 0.71 | MEN1 (0.39) | MEN1MAPK1KMT2AHDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881002-A1 | HCV NS-3 serine protease inhibitors | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-23 | — | — | EP | disclosed |